Entera Bio(US:ENTX) ZACKS·2024-08-15 17:06Core Viewpoint - Entera Bio Ltd. (ENTX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2024, Entera Bio is expected to earn -$0.23 per share, reflecting a 25.8% change from the previous year's reported number [8]. Analyst Sentiment and Market Position - Analysts have been consistently raising their earnings estimates for Entera Bio, with the Zacks Consensus Estimate increasing by 8% over the past three months [8]. - The upgrade to Zacks Rank 2 places Entera Bio in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].